Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11407183 | 0.89 | ALDH1A1 (0.70) | ALDH1A1LMNAATMMEN1KMT2A | |
| SCHEMBL15897586 | 0.87 | ALDH1A1 (0.57) | ALDH1A1LMNAATMMEN1KMT2A | |
| SCHEMBL2094230 | 0.85 | ALDH1A1 (0.65) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL18415468 | 0.85 | ALDH1A1 (0.87) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2094227 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2902943 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL8004976 | 0.82 | MDM2 (0.63) | ALDH1A1ATMMEN1KMT2ATP53 | |
| SCHEMBL4548130 | 0.82 | CNR1 (0.58) | ALDH1A1LMNAATMMEN1KMT2A | |
| SCHEMBL16857521 | 0.82 | MAPT (0.63) | ALDH1A1LMNAATMMEN1KMT2A | |
| SCHEMBL98684 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605105-B2 | Transition metal polymerization catalysts, their synthesis and use in olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080161517-A1 | Transition Metal Polymerization Catalysts, Their Synthesis And Use In Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-07-03 | — | — | US | disclosed |
| US-7351845-B2 | Transition metal polymerization catalysts, their synthesis and use in olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1846426-A1 | TRANSITION METAL POLYMERIZATION CATALYSTS, THEIR SYNTHESIS AND USE IN OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083549-A1 | TRANSITION METAL POLYMERIZATION CATALYSTS, THEIR SYNTHESIS AND USE IN OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173144-A1 | Transition metal polymerization catalysts, their synthesis and use in olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173144-A1 | Transition metal polymerization catalysts, their synthesis and use in olefin polymerization | SOD1, CCNT1, MYB | ALDH1A1 2080/4885LMNA 3996/4885ATM 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.